Medullary Thyroid Cancer - Pipeline Review, H2 2016

  • ID: 3845348
  • Drug Pipelines
  • 100 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Immunomedics, Inc.
  • Novartis AG
  • MORE
Medullary Thyroid Cancer - Pipeline Review, H2 2016

Summary

‘Medullary Thyroid Cancer - Pipeline Review, H2 2016’, provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Immunomedics, Inc.
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Medullary Thyroid Cancer Overview

Therapeutics Development

Pipeline Products for Medullary Thyroid Cancer - Overview

Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis

Medullary Thyroid Cancer - Therapeutics under Development by Companies

Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes

Medullary Thyroid Cancer - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Medullary Thyroid Cancer - Products under Development by Companies

Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes

Medullary Thyroid Cancer - Companies Involved in Therapeutics Development

AbbVie Inc

Advenchen Laboratories, LLC

Bayer AG

Boehringer Ingelheim GmbH

Celgene Corporation

Hutchison MediPharma Limited

Immunomedics, Inc.

Nerviano Medical Sciences S.r.l.

Novartis AG

Pfizer Inc.

Medullary Thyroid Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AL-3818 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLM-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLM-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLM-94 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nintedanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMS-616 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

regorafenib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rovalpituzumab tesirine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TF-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Medullary Thyroid Cancer - Dormant Projects

Medullary Thyroid Cancer - Discontinued Products

Medullary Thyroid Cancer - Product Development Milestones

Featured News & Press Releases

Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Medullary Thyroid Cancer, H2 2016

Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Medullary Thyroid Cancer - Pipeline by AbbVie Inc, H2 2016

Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016

Medullary Thyroid Cancer - Pipeline by Bayer AG, H2 2016

Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H2 2016

Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016

Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H2 2016

Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016

Medullary Thyroid Cancer - Pipeline by Novartis AG, H2 2016

Medullary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Medullary Thyroid Cancer - Dormant Projects, H2 2016

Medullary Thyroid Cancer - Discontinued Products, H2 2016 97List of Figures

Number of Products under Development for Medullary Thyroid Cancer, H2 2016

Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Immunomedics, Inc.
  • Novartis AG
  • MORE
According to our recently published report 'Medullary Thyroid Cancer – Pipeline Review, H2 2016'; Medullary Thyroid Cancer pipeline therapeutics constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says: Medullary Thyroid Cancer Medullary thyroid cancer (MTC) is a form of thyroid cancer that originates from the parafollicular cells of the thyroid gland. The parafollicular cells secrete the hormone calcitonin. The calcitonin hormone works together with the parathyroid hormone (a protein hormone secreted by parathyroid cells) to regulate calcium levels in the body. The symptoms associated with MTC are similar to other forms of thyroid cancer. They include a visible lump (nodule), the sensation of a lump with swallowing, hoarseness or enlarged lymph nodes that do not go away. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

The report 'Medullary Thyroid Cancer – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 8 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
Advenchen Laboratories, LLC
Bayer AG
Boehringer Ingelheim GmbH
Celgene Corporation
Hutchison MediPharma Limited
Immunomedics, Inc.
Nerviano Medical Sciences S.r.l.
Novartis AG
Pfizer Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll